Unité de Fabrication des Médicaments Past Earnings Performance
Past criteria checks 1/6
Unité de Fabrication des Médicaments's earnings have been declining at an average annual rate of -21.2%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 6.2% per year. Unité de Fabrication des Médicaments's return on equity is 6.3%, and it has net margins of 4.6%.
Key information
-21.2%
Earnings growth rate
-22.2%
EPS growth rate
Pharmaceuticals Industry Growth
12.4%
Revenue growth rate
6.2%
Return on equity
6.3%
Net Margin
4.6%
Last Earnings Update
30 Jun 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Unité de Fabrication des Médicaments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
BVMT:UMED Revenue, expenses and earnings (TND Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 24
141
6
21
0
31 Mar 24
139
6
20
0
31 Dec 23
136
6
20
0
30 Sep 23
126
9
19
0
30 Jun 23
115
13
18
0
31 Mar 23
106
10
17
0
31 Dec 22
96
8
17
0
30 Sep 22
91
6
17
0
30 Jun 22
86
5
17
0
31 Mar 22
85
7
16
0
31 Dec 21
85
9
15
0
30 Sep 21
85
7
15
0
30 Jun 21
86
6
15
0
31 Mar 21
89
7
15
0
31 Dec 20
91
7
15
0
30 Sep 20
93
10
15
0
30 Jun 20
95
12
15
0
31 Mar 20
101
15
15
0
31 Dec 19
107
18
15
0
30 Sep 19
107
20
15
0
30 Jun 19
107
22
14
0
31 Mar 19
97
20
14
0
31 Dec 18
87
18
13
0
30 Sep 18
80
16
13
0
30 Jun 18
73
13
13
0
31 Mar 18
72
13
13
0
31 Dec 17
70
13
12
0
30 Sep 17
69
12
12
0
30 Jun 17
68
11
11
0
31 Mar 17
66
11
11
0
31 Dec 16
65
11
10
0
30 Sep 16
63
13
10
0
30 Jun 16
61
15
9
0
31 Mar 16
60
14
9
0
31 Dec 15
59
13
9
0
30 Sep 15
60
12
9
0
30 Jun 15
60
11
8
0
31 Mar 15
59
12
8
0
31 Dec 14
58
12
8
0
31 Dec 13
47
10
8
0
Quality Earnings: UMED has high quality earnings.
Growing Profit Margin: UMED's current net profit margins (4.6%) are lower than last year (11.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UMED's earnings have declined by 21.2% per year over the past 5 years.
Accelerating Growth: UMED's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: UMED had negative earnings growth (-51%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16%).
Return on Equity
High ROE: UMED's Return on Equity (6.3%) is considered low.